Recommendations of the French Society for Rheumatology regarding TNFα antagonist therapy in patients with rheumatoid arthritis

Pincus, 2005, Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985, Arthritis Rheum, 52, 1009, 10.1002/art.20941 Grigor, 2004, Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial, Lancet, 364, 263, 10.1016/S0140-6736(04)16676-2 Goekoop-Ruiterman, 2005, Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial, Arthritis Rheum, 52, 3381, 10.1002/art.21405 Goekoop-Ruiterman, 2007, Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial, Ann Intern Med, 146, 406, 10.7326/0003-4819-146-6-200703200-00005 Emery, 2002, Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide, Ann Rheum Dis, 61, 290, 10.1136/ard.61.4.290 Pham, 2005, Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion, Joint Bone Spine, 72, 222, 10.1016/j.jbspin.2004.10.010 Gossec, 2005, Structural evaluation in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion, Joint Bone Spine, 72, 229, 10.1016/j.jbspin.2004.10.011 Fautrel, 2005, Role and modalities of information and education in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion, Joint Bone Spine, 72, 163, 10.1016/j.jbspin.2004.09.010 Combe, 2007, EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics, Ann Rheum Dis, 66, 34, 10.1136/ard.2005.044354 Emery, 2001, WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis, Rheumatology (Oxford), 40, 699, 10.1093/rheumatology/40.6.699 Salvarani, 2004, Recommendations for the appropriate use of anti-TNFalpha therapy in patients with psoriatic arthritis, Italian Rheumatology Society. Reumatismo, 56, 133 Ledingham, 2005, Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001), Rheumatology (Oxford), 44, 157, 10.1093/rheumatology/keh464 Furst, 2004, Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, Ann Rheum Dis, 63, ii2, 10.1136/annrheumdis-2013-203348 Blumenauer, 2002, Infliximab for the treatment of rheumatoid arthritis, Cochrane Database Syst Rev, CD003785 Blumenauer, 2003, Etanercept for the treatment of rheumatoid arthritis, Cochrane Database Syst Rev, CD004525 Rau, 2002, Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials, Ann Rheum Dis, 61, ii70, 10.1136/ard.61.suppl_2.ii70 Jobanputra, 2002, The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation, Health Technol Assess, 6, 1, 10.3310/hta6210 Fautrel, 2006, Recommendations of the French Society for Rheumatology. TNFalpha antagonist therapy in rheumatoid arthritis, Joint Bone Spine, 73, 433, 10.1016/j.jbspin.2006.04.001 2001 1999 Shekelle, 1999, Clinical guidelines: developing guidelines, BMJ, 318, 593, 10.1136/bmj.318.7183.593 van Riel, 1996, Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers, Br J Rheumatol, 35, 4, 10.1093/rheumatology/35.suppl_2.4 Fransen, 2005, Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial, Ann Rheum Dis, 64, 1294, 10.1136/ard.2004.030924 Leeb, 2004, The DAS28 in rheumatoid arthritis and fibromyalgia patients, Rheumatology (Oxford), 43, 1504, 10.1093/rheumatology/keh322 Gardiner, 2005, A potential pitfall in the use of the Disease Activity Score (DAS28) as the main response criterion in treatment guidelines for patients with rheumatoid arthritis, Ann Rheum Dis, 64, 506, 10.1136/ard.2004.025015 del Rincon, 2004, Effect of glucocorticoids on the arteries in rheumatoid arthritis, Arthritis Rheum, 50, 3813, 10.1002/art.20661 Strand, 2003, Low dose glucocorticoids in early rheumatoid arthritis, Clin Exp Rheumatol, 21, S186 Curtis, 2007, Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists, Arthritis Rheum, 56, 1125, 10.1002/art.22504 Schneeweiss, 2006, Anti-TNF alpha inhibitors and the risk of severe bacterial infection (Abstr), Arthritis Rheum, 54, S548 Capell, 1991, Rheumatoid arthritis: workload and outcome over 10years, Q J Med, 79, 461 Ingeman-Nielsen, 1983, Clinical synovitis and radiological lesions in rheumatoid arthritis. A prospective study of 25 patients during treatment with remission-inducing drugs, Scand J Rheumatol, 12, 237, 10.3109/03009748309098540 Maravic, 1999, Radiologic progression in early rheumatoid arthritis treated with methotrexate, J Rheumatol, 26, 262 Molenaar, 2004, Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission, Arthritis Rheum, 50, 36, 10.1002/art.11481 Mulherin, 1996, Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ, Br J Rheumatol, 35, 1263, 10.1093/rheumatology/35.12.1263 Sany, 1990, Radiologic progression during intramuscular methotrexate treatment of rheumatoid arthritis, J Rheumatol, 17, 1636 Scott, 1984, Progression of radiological changes in rheumatoid arthritis, Ann Rheum Dis, 43, 8, 10.1136/ard.43.1.8 Cohen, 2007, Radiological damage in patients with rheumatoid arthritis on sustained remission, Ann Rheum Dis, 66, 358, 10.1136/ard.2006.057497 St Clair, 2004, Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial, Arthritis Rheum, 50, 3432, 10.1002/art.20568 Bathon, 2000, A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis, N Engl J Med, 343, 1586, 10.1056/NEJM200011303432201 Genovese, 2002, Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes, Arthritis Rheum, 46, 1443, 10.1002/art.10308 Breedveld, 2004, Infliximab in active early rheumatoid arthritis, Ann Rheum Dis, 63, 149, 10.1136/ard.2003.013961 Bongartz, 2006, Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials, JAMA, 295, 2275, 10.1001/jama.295.19.2275 Askling, 2005, Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists, Ann Rheum Dis, 64, 1414, 10.1136/ard.2004.033241 Askling, 2005, Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists, Ann Rheum Dis, 64, 1421, 10.1136/ard.2004.033993 Askling, 2005, Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden, Arthritis Rheum, 52, 1986, 10.1002/art.21137 Geborek, 2005, Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas, Ann Rheum Dis, 64, 699, 10.1136/ard.2004.030528 Chakravarty, 2005, Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors, J Rheumatol, 32, 2130 Dixon, 2006, Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register, Arthritis Rheum, 54, 2368, 10.1002/art.21978 Ting, 2006, Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients, Int J Dermatol, 45, 689, 10.1111/j.1365-4632.2005.02642.x Sellam, 2007, Use of infliximab to treat psoriatic arthritis in HIV-positive patients, Joint Bone Spine, 74, 197, 10.1016/j.jbspin.2006.05.012 Kristensen, 2006, Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden, Arthritis Res Ther, 8, R174, 10.1186/ar2084 Gomez-Reino, 2006, Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period, Arthritis Res Ther, 8, R29, 10.1186/ar1881 Hyrich, 2006, Arthritis Rheum, 54, 1786, 10.1002/art.21830 Bingham, 2006, Number needed to treat comparison of biologic agents in rheumatoid arthritis (Abstr), Arthritis Rheum, 54, S342 Listing, 2005, Infections in patients with rheumatoid arthritis treated with biologic agents, Arthritis Rheum, 52, 3403, 10.1002/art.21386 Hyrich, 2006, Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study, Arthritis Rheum, 56, 13, 10.1002/art.22331 Carmona, 2006, Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER, Arthritis Res Ther, 8, R72, 10.1186/ar1941 Gomez-Reino, 2003, Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report, Arthritis Rheum, 48, 2122, 10.1002/art.11137 Furst, 2006, Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection, Semin Arthritis Rheum, 36, 159, 10.1016/j.semarthrit.2006.02.001 Wallis, 2004, Granulomatous infectious diseases associated with tumor necrosis factor antagonists, Clin Infect Dis, 38, 1261, 10.1086/383317 Saliu, 2006, Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity, J Infect Dis, 194, 486, 10.1086/505430 Tubach, 2006, Le risque tuberculeux persiste chez les patients traités par anti-TNF. Identification des facteurs de risque chez ces patients, Rev Rhum Ed Fr, 73, 1028, 10.1016/j.rhum.2006.10.010 Hamdi, 2006, Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists, Arthritis Res Ther, 8, R114, 10.1186/ar1994 Wolfe, 2004, Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients, Arthritis Rheum, 50, 1740, 10.1002/art.20311 Maini, 1998, Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis, Arthritis Rheum, 41, 1552, 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W Klareskog, 2004, Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial, Lancet, 363, 675, 10.1016/S0140-6736(04)15640-7 Breedveld, 2004, Early treatment of rheumatoid arthritis (RA) with adalimumab (HUMIRA) plus methotrexate vs. adalimumab alone vs. methotrexate alone: the PREMIER study, Arthritis Rheum, 50, L5 Hyrich, 2006, Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register, Rheumatology (Oxford), 45, 1558, 10.1093/rheumatology/kel149 van Riel, 2006, Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study, Ann Rheum Dis, 65, 1478, 10.1136/ard.2005.043299 Flendrie, 2003, Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis, Ann Rheum Dis, 62, ii30 Flendrie, 2005, The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study, Rheumatology (Oxford), 44, 472, 10.1093/rheumatology/keh508 Godinho, 2004, Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis, Clin Exp Rheumatol, 22, 328 Cannon, 2004, Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD, J Rheumatol, 31, 1906 Hansen, 2004, The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis, Arthritis Rheum, 51, 228, 10.1002/art.20228 Kiely, 2002, Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study, Rheumatology (Oxford), 41, 631, 10.1093/rheumatology/41.6.631 Ferraccioli, 2002, Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trial, Rheumatology (Oxford), 41, 1109, 10.1093/rheumatology/41.10.1109 Furst, 2003, Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis), J Rheumatol, 30, 2563 Temekonidis, 2002, Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis, Ann Rheum Dis, 61, 822, 10.1136/ard.61.9.822 Mariette, 2004, Adalimumab (HUMIRA) is as effective when used in combination with other DMARDs as with methotrexate in treating rheumatoid arthritis: the ReAct study, Arthritis Rheum, 50, S183 Perdriger, 2006, Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice, J Rheumatol, 33, 865 O'Dell, 2006, Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis, J Rheumatol, 33, 213 Combe, 2006, Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison, Ann Rheum Dis, 65, 1357, 10.1136/ard.2005.049650 Bartelds, 2007, Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis, Ann Rheum Dis, 66, 921, 10.1136/ard.2006.065615 Wolfe, 2004, Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy, Arthritis Rheum, 50, 372, 10.1002/art.20009 Durez, 2005, A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3mg/kg every 8weeks can be effective: a Belgian prospective study, Rheumatology (Oxford), 44, 465, 10.1093/rheumatology/keh494 Gomez-Puerta, 2004, Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy, Ann Rheum Dis, 63, 896 van Vollenhoven, 2004, Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect, Ann Rheum Dis, 63, 426, 10.1136/ard.2003.010967 Cohen, 2004, Secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis, Ann Rheum Dis, 63, 209, 10.1136/ard.2003.013532 Kapral, 2006, Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure, Arthritis Res Ther, 8, R46, 10.1186/ar1902 Bombardieri, 2004, Efficacy evaluation of adalimumab (HUMIRA) in patients with single and multiple prior biologics in the ReAct trial, Arthritis Rheum, 50, S187 Keystone, 2004, Switching anti-TNF therapy: real-world outcome of patients with rheumatoid arthritis who failed either infliximab or etanercept treatment and switched to another anti-TNF inhibitor, Arthritis Rheum, 50, S400 van Vollenhoven, 2003, Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense, Ann Rheum Dis, 62, 1195, 10.1136/ard.2003.009589 Wick, 2005, Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital, Scand J Rheumatol, 34, 353, 10.1080/03009740510026887 Ang, 2003, Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?, J Rheumatol, 30, 2315 Brocq, 2002, Etanercept–infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha, Presse Med, 31, 1836 Brocq, 2004, Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy: experience with 18 patients, Joint Bone Spine, 71, 601, 10.1016/j.jbspin.2004.07.009 Hansen, 2004, The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis, J Rheumatol, 31, 1098 Haraoui, 2004, Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept, J Rheumatol, 31, 2356 Finckh, 2007, B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents, Arthritis Rheum, 56, 1417, 10.1002/art.22520 Schiff, 2004, Significant clinical improvements at 6months are sustained over 4years in patients with rheumatoid arthritis treated with adalimumab (HUMIRA) plus methotrexate, Arthritis Rheum, 50, S182 Solau-Gervais, 2006, Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody, Rheumatology (Oxford), 45, 1121, 10.1093/rheumatology/kel054 Pham, 2005, Anti-TNF alpha therapy and safety monitoring: clinical tool guide elaborated by the Club Rhumatismes et Inflammation, Joint Bone Spine, 72, S1 Durieux, 1999, Does continuing medical education improve the way physicians conduct their practice?, Presse Med, 28, 468 Durieux, 2000, From clinical recommendations to mandatory practice. The introduction of regulatory practice guidelines in the French healthcare system, Int J Technol Assess Health Care, 16, 969, 10.1017/S0266462300103046 Smolen, 2000, Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis, Ann Rheum Dis, 59, 504, 10.1136/ard.59.7.504 Furst, 2006, Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection, Ann Rheum Dis, 65, iii2